Sareum Holdings is a drug discovery and development company based in the United Kingdom. It designs small molecule kinase inhibitors, compounds that act on specific enzymes involved in disease processes. Its research focuses on treatments for cancer and autoimmune conditions, and it advances its programmes through partnerships and licensing arrangements with pharmaceutical companies. The company works at the early stages of medicine development, from laboratory discovery through to studies that prepare candidates for clinical testing.
The shares are listed on the London Exchange in UK under the code SAR, and the price on this page is in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Fair price profile
Ranks #888 of 3787 on the London Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendStrong
75/100
Trading above its long-term averages and near its highs.
See the numbers →
Above 200-day average24.0%
From 52-week high-25.7%
MomentumStrong
89/100
Rising faster than most stocks on this exchange.
See the numbers →
3-month return14.6%
6-month return31.0%
12-month, skipping last month81.5%
Stability (higher is calmer)Weak
28/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)69.0%
Worst drawdown, 1 year (smaller is calmer)-33.3%
LiquidityStrong
73/100
Trades actively.
See the numbers →
Avg daily value traded9.62M GBX
Zero-volume days8.3%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
52-wk range 11.75 – 40.00Daily closes, split-adjusted
Signals
50-day average29.82
200-day average22.18
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)1.30
Technical summary
Daily
Neutral
6 bullish · 2 neutral · 8 bearish
Weekly
Bullish
7 bullish · 1 neutral · 4 bearish
Monthly
Bullish
5 bullish · 1 neutral · 2 bearish
Moving averages (daily)
SMA 10
27.95
Bearish
EMA 10
28.11
Bearish
SMA 20
29.45
Bearish
EMA 20
28.94
Bearish
SMA 50
29.82
Bearish
EMA 50
28.72
Bearish
SMA 100
26.26
Bullish
EMA 100
26.63
Bullish
SMA 200
22.18
Bullish
EMA 200
23.91
Bullish
Oscillators (daily)
RSI (14)
35.05
Neutral
MACD (12, 26)
-0.82
Bearish
Momentum (12)
-9.84
Bearish
Stochastic %K (14)
14.93
Bullish
Williams %R (14)
-85.07
Bullish
CCI (20)
-85.83
Neutral
Pivot points (classic, last session)
S3
27.50
S2
27.50
S1
27.50
Pivot
27.50
R1
27.50
R2
27.50
R3
27.50
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in GBX. Educational only, not financial advice.
